Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

Phase 1 Completed 55 enrolled Disc Medicine, Inc

RandomizedSequentialQuadruple-blindTreatment

Summary

This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia.

Timeline

Start: 2023-04-04
Primary completion: 2025-10-09
Completion: 2026-01-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DISC-0974	Monoclonal antibody	—	Subcutaneous

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

Summary

Timeline

Drugs

Indications